- TOP >
- Drug Discovery & Development Business
Drug Discovery and Development
The driving force for innovative drug creation revolutionizes the drug discovery process.
The mission of R&D-oriented pharmaceutical companies is none other than the continuous creation of innovative pharmaceutical products. Daiichi Sankyo RD Novare has advanced drug discovery platforms built in-house, consisting of state-of-the-art drug discovery technologies and high quality clinical development. We aim to become a driving force for drug discovery by creating innovative drug discovery processes prior to changing drug discovery needs.
Accelerating R&D of New Drugs
Daiichi Sankyo RD Novare resolves bottlenecks in the research and development stages of pharmaceutical products through its advanced drug discovery platform. We are working in close collaboration with project members to achieve the criteria required by each R&D stage as soon as possible. Daiichi Sankyo RD Novare's advanced expertise in various areas leads Daiichi Sankyo's drug discovery innovation and contributes to establishing competitive advantage in the pharmaceutical industry.
Transforming the Drug Discovery Process.
Further evolution of drug discovery platforms will transform the drug discovery process. We are working to expand the application of core technologies developed by small molecule drug discovery to new modalities, create translational research infrastructures that enable drug discovery based on pathological mechanisms, build information analysis infrastructures for the handling of large-scale data, and introduce advanced processes to accelerate initial development in the oncology area. In addition, through active collaboration with medical institutions, academia, and corporations with innovative new technologies, we will build a productive drug discovery ecosystem.
Three R&D Units to Enhance the Productivity of Drug Discovery
Daiichi Sankyo RD Novare's business consists of three units: the Drug Discovery Research Unit, which is responsible for identifying compounds with properties as drugs such as drug efficacy, kinetics, and safety; the Translational Research (TR: Translational Research) Unit, which aims to improve the probabilities of successful drug discovery through non-clinical and clinical research such as pathology, genomics, and bioinformatics; and the Clinical Development Unit, which is responsible for monitoring and data collection and analysis integrated with the medical field during the clinical development phase.
Evolving Drug Discovery Platforms
Daiichi Sankyo RD Novare has multiple drug discovery platforms that pursue the expertise of each unit, which consist of various "core technologies" developed by experts in each area. Ensuring the effective operation of these "drug discovery platforms" enables the significant acceleration of the drug discovery research and development process.
Core Technologies of
Daiichi Sankyo RD Novare
Our core technologies are technologies with competitive advantages, which are the key to acquiring a unique position in the pharmaceutical industry, based on core technologies developed in-house. Individual core technologies are generated through collaboration / technological development based on open innovation and trial and error by in-house experts.
Daiichi Sankyo RD Novare
Drug Discovery Platforms
In order to improve the productivity of the drug discovery process and provide flexible problem-solving according to theme, we combine the related core technologies to build the "drug discovery platform". The huge amount of data and expertise gained from R&D processes is converged and continues to evolve, which is "Daiichi Sankyo RD Novare's "drug discovery platforms".